What is the recommended treatment for acute pyelonephritis?

Treatment of Acute Pyelonephritis

For uncomplicated acute pyelonephritis, treat outpatients with oral fluoroquinolones (ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg daily for 5 days) as first-line therapy, or use oral cephalosporins as equally effective alternatives when fluoroquinolone resistance exceeds 10% or to minimize adverse effects. 1

Outpatient Oral Treatment

First-Line Agents

• Fluoroquinolones are the preferred empirical treatment for uncomplicated pyelonephritis when local resistance rates are <10% 1:

  • Ciprofloxacin 500-750 mg twice daily for 7 days 1
  • Levofloxacin 750 mg once daily for 5 days 1

• Oral cephalosporins are equally effective alternatives with no difference in UTI recurrence rates compared to fluoroquinolones 1, 2:

  • Cefpodoxime 200 mg twice daily for 10 days 1
  • Ceftibuten 400 mg once daily for 10 days 1
  • Must administer an initial IV dose of long-acting cephalosporin (e.g., ceftriaxone) when using oral cephalosporins empirically 1

Alternative Agent

• Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days can be used if local resistance patterns permit 1

Agents to Avoid

• Do not use nitrofurantoin, oral fosfomycin, or pivmecillinam for pyelonephritis due to insufficient efficacy data 1

Inpatient Parenteral Treatment

Indications for Hospitalization

Admit patients with 1, 3:

• Complicated infections or obstructive features 1
• Sepsis or hemodynamic instability 1
• Persistent vomiting preventing oral intake 3
• Failed outpatient treatment 3
• Pregnancy 1

Initial IV Regimens

Choose based on local resistance patterns and severity 1:

Standard empirical options:

• Ciprofloxacin 400 mg IV twice daily 1
• Levofloxacin 750 mg IV once daily 1
• Ceftriaxone 1-2 g IV once daily 1
• Cefotaxime 2 g IV three times daily 1
• Cefepime 1-2 g IV twice daily 1
• Piperacillin-tazobactam 2.5-4.5 g IV three times daily 1
• Gentamicin 5 mg/kg IV once daily (with or without ampicillin) 1
• Amikacin 15 mg/kg IV once daily 1

Reserve for multidrug-resistant organisms only (based on early culture results) 1:

• Carbapenems (imipenem 0.5 g three times daily, meropenem 1 g three times daily) 1
• Ceftolozane-tazobactam 1.5 g three times daily 1
• Ceftazidime-avibactam 2.5 g three times daily 1
• Cefiderocol 2 g three times daily 1

Duration of Treatment

• Fluoroquinolones: 5-7 days total 1, 4
• Dose-optimized β-lactams: 7 days total 1, 4
• Trimethoprim-sulfamethoxazole: 14 days 1

Seven days of treatment is equivalent to longer courses (10-14 days) for clinical and microbiological success in uncomplicated cases 4. However, shorter courses may have higher recurrence rates within 4-6 weeks and should be tailored to local policies 1.

Critical Management Considerations

Imaging for Obstruction

• Obtain urgent imaging (ultrasound or CT) within 72 hours if no clinical improvement, or immediately if clinical deterioration occurs 1
• Obstructive pyelonephritis can rapidly progress to urosepsis and requires urgent urinary drainage 1, 5
• In obstructive cases with septic shock, delayed drainage >12 hours is associated with increased mortality 5

Culture and Susceptibility Testing

• Obtain urine cultures before initiating antibiotics 3
• Blood cultures are positive in approximately two-thirds of hospitalized patients but should be reserved for severe cases, immunocompromised patients, or uncertain diagnoses 3, 5
• Adjust empirical therapy once susceptibility results are available 1

Antimicrobial Resistance Patterns

• Fluoroquinolone resistance in E. coli ranges from 10% in community settings to 18% in hospitals 6
• Extended-spectrum beta-lactamase (ESBL)-producing organisms occur in approximately 10-11% of cases 6, 5
• Avoid fluoroquinolones empirically when local resistance exceeds 10% 1

Common Pitfalls

• Do not use aminoglycosides as monotherapy for pyelonephritis—they have not been adequately studied in this role and carry risks of nephrotoxicity and ototoxicity 1, 6
• Do not use oral cephalosporins without an initial IV loading dose of a long-acting agent like ceftriaxone, as oral formulations achieve significantly lower blood concentrations 1
• Do not delay imaging in patients who fail to improve within 72 hours—this may indicate obstruction, abscess formation, or resistant organisms 1
• Repeat urine culture 1-2 weeks after completing therapy to document microbiological cure 3

Complicated Pyelonephritis

For patients with complicating factors (obstruction, foreign bodies, immunosuppression, diabetes, multidrug-resistant organisms, pregnancy, or male sex), treatment duration and antibiotic selection require individualized approaches based on the specific complication 1. These patients generally require longer treatment courses and broader-spectrum coverage pending culture results 1.